Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIAMOND: Pyrotinib, Trastuzumab, and Dalpiciclib vs Docetaxel in Advanced HER2+ Breast Cancer
NCT07615751Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Feb 2025
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 3 trial of dalpiciclib in breast cancer, sponsored by Fudan University. Started Feb 2025; status: recruiting.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07615751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07615751.